Long-Term Efficacy of Implantable Cardioverter Defibrillator in Repaired Tetralogy of Fallot　― Role of Anti-tachycardia Pacing ―

Henmi, Ryuta; Ejima, Koichiro; Daigo, Yataro; Iwanami, Yuji; Nishimura, T; Takeuchi, Daiji; Toyohara, Keiko; Shoda, Morio; Hagiwara, Nobuhisa

doi:10.1253/circj.cj-16-0932

Cited by 8 publications

(3 citation statements)

References 27 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3–9 Tachyarrhythmias and bradyarrhythmias affect 20%–50% of adult patients with TOF and some of these patients will require cardiac implantable electronic devices (CIED) such as pace-maker and internal cardioverter defibrillators. 810–13…”

Section: Introductionmentioning

confidence: 99%

Cardiac implantable electronic devices in adults with tetralogy of Fallot

Egbe

Miranda

Madhavan

et al. 2018

Heart

View full text Add to dashboard Cite

BackgroundTachyarrhythmias and bradyarrhythmias affect 20%–50% of adult patients with tetralogy of Fallot (TOF) and some of these patients will require cardiac implantable electronic devices (CIED) such as pacemaker and/or internal cardioverter defibrillator.MethodsThe Mayo Adult Congenital Heart Disease database was queried for patients with repaired TOF and history of CIED implantation, 1990–2017. The study objectives were: (1) determine the occurrence of device-related complications defined as lead failure, lead recall, device infection and lead thrombus; and (2) determine the occurrence and risk factors for defibrillator shock.ResultsThere were 99 patients (age 46±14 years and 66 (66%) men) with CIED, and the CIEDs were 41 (41%) pacemakers and 73 (73%) defibrillators. Indication for defibrillator implantation was for primary prevention in 28 (38%) and secondary prevention in 45 (62%). Device-related complications occurred in 20 (20%) patients (lead failure 17, lead recall 4, device infection 12 and thrombus 3). Twenty-five per cent of all device infections occurred within 30 days from the time of device generator change. Annualised rates of appropriate and inappropriate shocks were 5.7% and 6.2%, respectively. The use of class III antiarrhythmic drug was protective against defibrillator shock.ConclusionThe current study provides useful outcome data to aid patient counselling and clinical decision-making. Further studies are required to explore ways to decrease the risk of postprocedural infection after device generator change, and to determine which patients will benefit from empirical antiarrhythmic therapy as a strategy to decrease incidence of inappropriate defibrillator shock.

show abstract

Section: Introductionmentioning

confidence: 99%

Cardiac implantable electronic devices in adults with tetralogy of Fallot

Egbe

Miranda

Madhavan

et al. 2018

Heart

View full text Add to dashboard Cite

show abstract

“…Um artigo de análise examinou a eficácia a longo prazo do cardioversor desfibrilador implantável (CDI) na Tetralogia de Fallot reparada, especialmente o papel da estimulação antitaquicardia. Os resultados indicaram uma eficácia notável dessa terapia, destacando sua importância no manejo de arritmias nesses pacientes (Henmi et al, 2017).…”

Section: Resultsunclassified

Avanços no tratamento e manejo da tetralogia de Fallot: Perspectivas atuais e futuras

Tenorio,

Barros,

Sampaio

et al. 2024

RSD

View full text Add to dashboard Cite

Os avanços no tratamento e manejo da Tetralogia de Fallot (TF) representam uma área de significativa importância na medicina pediátrica, demandando uma compreensão abrangente e atualizada para garantir a melhoria dos desfechos clínicos e a qualidade de vida dos pacientes afetados. A TF é uma condição cardíaca congênita complexa, caracterizada por quatro anormalidades específicas que comprometem o fluxo sanguíneo para os pulmões, resultando em hipoxemia crônica e outras complicações cardiovasculares. Este trabalho tem como objetivo analisar os avanços recentes e as perspectivas futuras no tratamento e manejo da TF, uma das cardiopatias congênitas mais prevalentes na infância. Para isso, serão revisados os principais métodos diagnósticos, as estratégias terapêuticas atuais e as abordagens emergentes na gestão dessa condição complexa. Para conduzir a revisão integrativa, foi realizada uma busca na base de dados eletrônicas, PubMed, com o objetivo de identificar estudos relevantes publicados nos últimos 10 anos (2015 a 2024). Os descritores MESH específicos utilizados foram “Tetralogy of Fallot”, “Diagnostic”, “Therapeutics”, “Drug therapy”. Esses termos foram selecionados para garantir a inclusão de estudos que abordassem diferentes aspectos relacionados à TF, desde novas terapias até diretrizes de manejo e previsões para o futuro.

show abstract

“…Transvenous systems offer the added benefit of anti-tachycardia pacing, which has the potential to be customized for patients with a secondary indica-tion [62], as well as bradycardia pacing for individuals with pre-existing conduction disease. When there is no pacing indication, an attractive alternative is an entirely subcutaneous device, which preserves venous access in younger patients and may circumvent the high risk of transvenous-related lead complications [63,64]. However, loss of anti-tachycardia pacing with subcutaneous ICDs can result in more shocks when compared to transvenous systems, which was highlighted by a study showing that 59% of VT in TOF patients with ICDs was terminated successfully through anti-tachycardia pacing [37].…”

Section: Implantable Cardiac Defibrillatorsmentioning

confidence: 99%

Evaluation and Management of Sudden Death Risk in Repaired Tetralogy of Fallot

Habib,

Srivasthan,

El Masry

2023

JPM

View full text Add to dashboard Cite

Although substantial progress has been made to prevent sudden cardiac death in repaired tetralogy of Fallot patients, ventricular arrhythmia and sudden death continue to be major causes of morbidity and mortality in these patients. Greater survival in contemporary cohorts has been attributed to enhanced surgical techniques, more effective management of heart failure, and increased efforts in risk stratification and management of ventricular arrhythmias. More recently, our understanding of predictive risk factors has evolved into personalized risk prediction tools that rely on comprehensive demographic, imaging, functional, and electrophysiological data. However, the universal applicability of these different scoring systems is limited due to differences between study cohorts, types of anatomic repair, imaging modalities, and disease complexity. Noninvasive risk stratification is critical to identify those who may derive benefit from catheter ablation or cardioverter defibrillator implantation for primary prevention. Ultimately, assessment and risk stratification by a multidisciplinary team is crucial to analyze the various complex factors for every individual patient and discuss further options with patients and their families.

show abstract

Long-Term Efficacy of Implantable Cardioverter Defibrillator in Repaired Tetralogy of Fallot　― Role of Anti-tachycardia Pacing ―

Cited by 8 publications

References 27 publications

Cardiac implantable electronic devices in adults with tetralogy of Fallot

Cardiac implantable electronic devices in adults with tetralogy of Fallot

Avanços no tratamento e manejo da tetralogia de Fallot: Perspectivas atuais e futuras

Evaluation and Management of Sudden Death Risk in Repaired Tetralogy of Fallot

Contact Info

Product

Resources

About

Long-Term Efficacy of Implantable Cardioverter Defibrillator in Repaired Tetralogy of Fallot ― Role of Anti-tachycardia Pacing ―

Cited by 8 publications

References 27 publications

Cardiac implantable electronic devices in adults with tetralogy of Fallot

Cardiac implantable electronic devices in adults with tetralogy of Fallot

Avanços no tratamento e manejo da tetralogia de Fallot: Perspectivas atuais e futuras

Evaluation and Management of Sudden Death Risk in Repaired Tetralogy of Fallot

Contact Info

Product

Resources

About

Long-Term Efficacy of Implantable Cardioverter Defibrillator in Repaired Tetralogy of Fallot　― Role of Anti-tachycardia Pacing ―